EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Real‐world treatment patterns and outcomes among patients with immune thrombocytopenia ( ITP ) who switched treatment from eltrombopag or romiplostim to avatrombopag in the United States: Results from the REAL ‐ AVA 3.5 study

Caroline Piatek iD, Abiola Oladapo, Scott Kolodny, Michael Vredenburg iD, Sarah Lucht, Emily Bland, Prathamesh Pathak, Bruce Feinberg, Hillary Maitland

British Journal of Haematology · 2026-06 · 208 (6) · 2185-2193

DOI: 10.1111/bjh.70531 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, online erschienen am 14.05.2026. Verfasst von Caroline Piatek und 8 weiteren Autor:innen. Beteiligte Einrichtung: University of Southern California, Los Angeles, California, USA. Hauptthemen laut MEDLINE: Benzoates, Hydrazines, Purpura, Thrombocytopenic, Idiopathic, Pyrazoles. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Swedish Orphan Biovitrum.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Real‐world data on treatment response after switching between thrombopoietin receptor agonists are limited for patients with immune thrombocytopenia (ITP). The objective of this study is to describe treatment patterns and outcomes in patients with primary ITP who switched from eltrombopag (ELT) or romiplostim (ROMI) to avatrombopag (AVA). We conducted a retrospective chart review study of adults with primary ITP who initiated ELT or ROMI on or after 1 July 2019, switched to AVA within 30 days of ELT/ROMI discontinuation and had ≥6 months follow‐up after AVA initiation. Patients were followed from AVA initiation until last contact, death or study end (21 March 2025), whichever occurred earliest. Response was defined as achieving ≥1 platelet count (PC) of ≥30 × 10 9 /L, ≥50 × 10 9 /L or ≥100 × 10 9 /L in the absence of rescue therapy. Response durability was the percentage of time on AVA with PCs above the response threshold among responders. Patients ( N = 201) most commonly discontinued ELT/ROMI due to lack of efficacy (59.2%). Among patients with baseline PCs

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BenzoatesHydrazinesPurpura, Thrombocytopenic, IdiopathicPyrazolesReceptors, FcRecombinant Fusion ProteinsThrombopoietinAdultAgedFemaleHumansMaleMiddle AgedDrug SubstitutionPlatelet CountReceptors, ThrombopoietinRetrospective StudiesTreatment OutcomeUnited StatesThiazolesThiophenes

Stichwörter der Autor:innen

immune thrombocytopeniaplatelet count

Substanzen

avatrombopagBenzoateseltrombopagHydrazinesPyrazolesReceptors, FcReceptors, ThrombopoietinRecombinant Fusion ProteinsromiplostimThrombopoietin

Autor:innen und Institutionen

  • University of Southern California, Los Angeles, California, USA.
  • Sobi Inc., Waltham, Massachusetts, USA.
  • Cardinal Health, Dublin, Ohio, USA.
  • University of Virginia, Charlottesville, Virginia, USA.

ORCID-Profile: Caroline Piatek, Michael Vredenburg

Förderung

  • Swedish Orphan Biovitrum

Zitieren

APA

Piatek, C., Oladapo, A., Kolodny, S., Vredenburg, M., Lucht, S., Bland, E., Pathak, P., Feinberg, B., & Maitland, H. (2026). Real‐world treatment patterns and outcomes among patients with immune thrombocytopenia ( ITP ) who switched treatment from eltrombopag or romiplostim to avatrombopag in the United States: Results from the REAL ‐ AVA 3.5 study. British Journal of Haematology, 208(6), 2185-2193. https://doi.org/10.1111/bjh.70531

Vancouver

Piatek C, Oladapo A, Kolodny S, Vredenburg M, Lucht S, Bland E, et al. Real‐world treatment patterns and outcomes among patients with immune thrombocytopenia ( ITP ) who switched treatment from eltrombopag or romiplostim to avatrombopag in the United States: Results from the REAL ‐ AVA 3.5 study. British Journal of Haematology. 2026;208(6):2185-2193. doi:10.1111/bjh.70531

BibTeX
@article{Piatek2026,
  author = {Piatek, Caroline and Oladapo, Abiola and Kolodny, Scott and Vredenburg, Michael and Lucht, Sarah and Bland, Emily and Pathak, Prathamesh and Feinberg, Bruce and Maitland, Hillary},
  title = {Real‐world treatment patterns and outcomes among patients with immune thrombocytopenia ( ITP ) who switched treatment from eltrombopag or romiplostim to avatrombopag in the United States: Results from the REAL ‐ AVA 3.5 study},
  journal = {British Journal of Haematology},
  year = {2026},
  volume = {208},
  number = {6},
  pages = {2185--2193},
  doi = {10.1111/bjh.70531}
}
Kostenlos starten →